(Total Views: 609)
Posted On: 09/07/2020 12:26:38 PM
Post# of 155735
We have licensing agreements for US HIV (Vyera) and for COVID worldwide (American Regent)
What I'm getting at is:. Is it possible that they may expedite HIV approval so that COVID is a label expansion?
It feels crazy to even say, and I know is not likely. But it's one way to increase the likelihood of acceptance of our small M2M study.
"Yes it was a small study, but combined with the data from their recently approved HIV studies, we have determined that the potential benefit of Leronlimab for COVID outweighs the potential risk (because the risk is 0)
What I'm getting at is:. Is it possible that they may expedite HIV approval so that COVID is a label expansion?
It feels crazy to even say, and I know is not likely. But it's one way to increase the likelihood of acceptance of our small M2M study.
"Yes it was a small study, but combined with the data from their recently approved HIV studies, we have determined that the potential benefit of Leronlimab for COVID outweighs the potential risk (because the risk is 0)
(3)
(0)
